Enhanced workflow for biomarker research

Thermo Fisher Scientific has acquired Intrinsic Bioprobes Inc., a manufacturer of immuno-enrichment, sample preparation tools used in quantitative mass spectrometry, with the intention of offering an enhanced solution for quantitative protein biomarker detection.

By adding Intrinsic Bioprobes’ mass spectrometric immunoassay (MSIA) technology to its portfolio, Thermo Fisher will be able to give researchers a complete, higher resolution view of the proteome as the technology allows enrichment of low-abundance proteins in biological samples providing greater specificity and sensitivity and offering clear advantages over ELISA and bead-based immunoassay formats.

“The Intrinsic Bioprobes’ portfolio will enhance Thermo Fisher’s position in the rapidly emerging field of clinical proteomics,” said Chuck Kummeth, president of Thermo Fisher’s laboratory consumables business. “It is a simple, yet powerful approach to uncovering the proteomic basis of disease, and it better positions us to support our customers in their efforts to realize the promise of personalized medicine.”

For further information visit ref="http://www.thermoscientific.com">www.thermoscientific.com